VCEL Logo

Vericel Corporation (VCEL) 

NASDAQ
Market Cap
$2.82B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
749 of 774
Rank in Industry
415 of 432

Largest Insider Buys in Sector

VCEL Stock Price History Chart

VCEL Stock Performance

About Vericel Corporation

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric …

Insider Activity of Vericel Corporation

Over the last 12 months, insiders at Vericel Corporation have bought $0 and sold $26.42M worth of Vericel Corporation stock.

On average, over the past 5 years, insiders at Vericel Corporation have bought $0 and sold $11.21M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,780 shares for transaction amount of $20,592 was made by Rubino Alan L (director) on 2018‑03‑16.

List of Insider Buy and Sell Transactions, Vericel Corporation

2024-11-14SalePresident and CEO
17,500
0.036%
$53.93$943,775-2.69%
2024-11-13SalePresident and CEO
17,500
0.0355%
$55.57$972,475-1.08%
2024-11-13Saledirector
7,000
0.0142%
$55.54$388,780-1.08%
2024-11-12Saledirector
2,500
0.0051%
$57.50$143,750-0.75%
2024-11-11Saledirector
2,500
0.0049%
$55.00$137,500-1.94%
2024-10-17SalePresident and CEO
17,500
0.0354%
$40.34$705,950+18.12%
2024-10-16SalePresident and CEO
17,500
0.0335%
$41.38$724,150+13.73%
2024-10-16Saledirector
5,833
0.0112%
$41.36$241,253+13.73%
2024-10-02Saledirector
5,833
0.0109%
$40.35$235,362+7.31%
2024-10-01SalePrincipal Accounting Officer
568
0.0011%
$41.90$23,799+8.26%
2024-09-18Saledirector
5,834
0.0117%
$45.54$265,680-6.45%
2024-09-12SalePresident and CEO
17,500
0.0354%
$43.90$768,250-0.52%
2024-09-11SalePresident and CEO
17,500
0.0355%
$43.37$758,9750.00%
2024-09-04Saledirector
5,000
0.0103%
$48.58$242,900-7.95%
2024-09-03SaleChief Medical Officer
10,000
0.0207%
$49.83$498,300-9.73%
2024-08-15SalePresident and CEO
17,500
0.0363%
$46.24$809,2000.00%
2024-08-14SalePresident and CEO
17,500
0.0355%
$45.17$790,4750.00%
2024-08-07Saledirector
7,000
0.0145%
$45.94$321,580+0.64%
2024-07-18SalePresident and CEO
17,500
0.0361%
$51.40$899,500-9.72%
2024-07-17SalePresident and CEO
17,500
0.0359%
$51.55$902,125-10.48%

Insider Historical Profitability

19.12%
Colangelo DominickPresident and CEO
220937
0.4476%
$57.07135+18.13%
ARMSTRONG R DOUGLAS PHDChairman and CEO
573763
1.1624%
$57.0725<0.0001%
MAYLEBEN TIMOTHY MPresident and CEO
133000
0.2695%
$57.0790+21.76%
MICHEL GERARD JCFO and VP, Corp. Development
123182
0.2496%
$57.07112+18.13%
CRESSWELL RONALD Mdirector
40000
0.081%
$57.0720+3.5%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$414.57M16.47.97M+0.41%+$1.69M0.01
Brown Capital Management$257.55M10.194.95M-27.39%-$97.17M4.58
The Vanguard Group$177.57M7.023.41M+1.17%+$2.05M<0.01
State Street$167.23M6.613.21M+20.63%+$28.6M0.01
Conestoga Capital Advisors, LLC$121.27M4.82.33M-0.37%-$449,973.001.78
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.